Investors have run back to the stock after promising clinical results.
News & Analysis: Deciphera Pharmaceuticals, Inc.
Good news on the trade front was instrumental in lifting many stocks on Tuesday.
Solid clinical results were just what the struggling pharma company needed.
Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today
Shares of all three cancer-focused companies shot higher after one of their peers got bought out for a sizable premium.
Can these red-hot drug stocks keep the momentum going?
The company is taking advantage of a recent surge in the stock price to raise growth capital.